EA200800427A1 - Композиция для сдерживания алкогольного обмена веществ и для уменьшения риска алкогольных заболеваний - Google Patents

Композиция для сдерживания алкогольного обмена веществ и для уменьшения риска алкогольных заболеваний

Info

Publication number
EA200800427A1
EA200800427A1 EA200800427A EA200800427A EA200800427A1 EA 200800427 A1 EA200800427 A1 EA 200800427A1 EA 200800427 A EA200800427 A EA 200800427A EA 200800427 A EA200800427 A EA 200800427A EA 200800427 A1 EA200800427 A1 EA 200800427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
substances
risk
reduce
food
Prior art date
Application number
EA200800427A
Other languages
English (en)
Other versions
EA012753B1 (ru
Inventor
Маркус Граф вон Матушка-Грейффенклау
Original Assignee
Тима Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/009147 external-priority patent/WO2007016949A1/en
Priority claimed from PCT/EP2005/009152 external-priority patent/WO2007016954A1/en
Priority claimed from PCT/EP2005/009153 external-priority patent/WO2007016955A1/en
Priority claimed from PCT/EP2005/009149 external-priority patent/WO2007016951A1/en
Priority claimed from PCT/EP2005/009150 external-priority patent/WO2007016952A1/en
Priority claimed from PCT/EP2005/009148 external-priority patent/WO2007016950A1/en
Application filed by Тима Фаундейшн filed Critical Тима Фаундейшн
Publication of EA200800427A1 publication Critical patent/EA200800427A1/ru
Publication of EA012753B1 publication Critical patent/EA012753B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

Данное изобретение относится к композиции веществ, в частности пищевой композиции, диетической или пищевой добавке и фармацевтической композиции. Указанная композиция уменьшает риск невропатических или нейродегенеративных заболеваний, включая болезнь Альцгеймера с поздним началом, и рака, в частности рака поджелудочной железы, рака пищевода, рака верхней части пищевого тракта, рака печени, рака ободочной и прямой кишки, рака легких и/или рака молочной железы, в особенности риск упомянутых заболеваний, вызываемый наркотиком и/или алкоголем. В этом смысле данное изобретение также направлено на композицию, в частности пищевую композицию, диетическую или пищевую добавку и фармацевтическую композицию, которая сдерживает и/или замедляет процесс деградации алкоголя в теле человека.
EA200800427A 2005-07-29 2006-07-27 Композиция для сдерживания алкогольного метаболизма и для уменьшения риска заболеваний, вызванных алкоголем EA012753B1 (ru)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
EP05016566 2005-07-29
EP05016565 2005-07-29
EP05016567 2005-07-29
EP05016563 2005-07-29
EP05016568 2005-07-29
EP05016564 2005-07-29
PCT/EP2005/009147 WO2007016949A1 (en) 2005-07-29 2005-08-24 Composition for reducing the risc of alcohol induced neuropathy
PCT/EP2005/009152 WO2007016954A1 (en) 2005-07-29 2005-08-24 Composition for reducing drug or alcohol induced breast cancer risk
PCT/EP2005/009153 WO2007016955A1 (en) 2005-07-29 2005-08-24 Alcohol metabolism moderating composition
PCT/EP2005/009151 WO2007016953A1 (en) 2005-07-29 2005-08-24 Composition for reducing alcohol induced liver cancer risk
PCT/EP2005/009149 WO2007016951A1 (en) 2005-07-29 2005-08-24 Composition for reducing the risc of alcohol induced pancreatic cancer
PCT/EP2005/009150 WO2007016952A1 (en) 2005-07-29 2005-08-24 Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer
PCT/EP2005/009148 WO2007016950A1 (en) 2005-07-29 2005-08-24 Composition for reducing the risk of alcohol induced neurodegenerative disease
PCT/EP2006/007466 WO2007017139A1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases

Publications (2)

Publication Number Publication Date
EA200800427A1 true EA200800427A1 (ru) 2008-06-30
EA012753B1 EA012753B1 (ru) 2009-12-30

Family

ID=39573667

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800427A EA012753B1 (ru) 2005-07-29 2006-07-27 Композиция для сдерживания алкогольного метаболизма и для уменьшения риска заболеваний, вызванных алкоголем

Country Status (19)

Country Link
US (2) US8580750B2 (ru)
EP (1) EP1909600B1 (ru)
JP (2) JP5371428B2 (ru)
KR (2) KR101487848B1 (ru)
CN (1) CN101232822B (ru)
AT (1) ATE554663T1 (ru)
AU (1) AU2006278823B2 (ru)
CA (1) CA2611389C (ru)
CY (1) CY1113015T1 (ru)
DK (1) DK1909600T3 (ru)
EA (1) EA012753B1 (ru)
ES (1) ES2386460T3 (ru)
HK (1) HK1117709A1 (ru)
HR (1) HRP20120489T1 (ru)
PL (1) PL1909600T3 (ru)
PT (1) PT1909600E (ru)
SI (1) SI1909600T1 (ru)
UA (1) UA94713C2 (ru)
WO (1) WO2007017139A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633192B2 (en) 2006-12-15 2014-01-21 Tima Foundation Compositions and uses thereof
KR101487852B1 (ko) * 2006-12-15 2015-01-29 티마 파운데이션 신규조성물 및 그 용도
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
AU2009206753B2 (en) * 2008-01-24 2014-07-03 Raptor Therapeutics Inc. Protopanaxadiol-type ginsenoside compositions and uses thereof
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
KR20110115862A (ko) * 2010-04-16 2011-10-24 씨제이제일제당 (주) 숙취 해소 및 예방용 조성물과 이를 이용한 음주전 후 숙취해소용 음료
WO2012095509A1 (en) * 2011-01-14 2012-07-19 Tima Foundation Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases
DE102011001768A1 (de) 2011-04-04 2012-10-04 Gunnar Frank Präparat oder Nahrungsergänzungsmittel
ES2762451T3 (es) * 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
KR20140136915A (ko) * 2011-11-15 2014-12-01 티마 파운데이션 세포손상 효과에 대한 보호를 제공하는 조성물
EP2594141A1 (en) * 2011-11-15 2013-05-22 TIMA Foundation Composition for protection against cell-damaging effects
US20150087702A1 (en) * 2011-11-22 2015-03-26 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
CN110051672A (zh) * 2012-07-09 2019-07-26 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
US9622999B2 (en) * 2013-11-06 2017-04-18 Salim JARROUJ Composition and method for increasing the rate of alcohol metabolism and preventing hangover symptoms
KR20170082527A (ko) 2014-11-07 2017-07-14 가부시키가이샤 니찌레이 바이오사이언스 알코올 대사 촉진제
CN109562090A (zh) 2016-06-06 2019-04-02 凯达普特凯特有限公司 用于治疗宿醉的l-半胱胺酸、抗坏血酸和维生素b3的组合物
JP6935994B2 (ja) * 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
US11166930B2 (en) * 2016-11-17 2021-11-09 Retrotope, Inc. Isotopically modified components and therapeutic uses thereof
KR102150040B1 (ko) * 2018-10-16 2020-08-31 한국과학기술원 4-메틸피라졸을 포함하는 간암 예방 또는 치료용 조성물
CN109125310A (zh) * 2018-11-06 2019-01-04 河北工业大学 琥珀酸在抑制Kv10.1离子通道活性中的应用和药物
CN110339233B (zh) * 2019-04-01 2021-10-19 山东济世药业有限公司 一种用于防治酒精性肝损伤的组合物及其制备方法和用途
CN114081891A (zh) * 2020-08-24 2022-02-25 山西好医生药业有限公司 一种五维葡萄糖的制备工艺及其应用
JP2022132160A (ja) * 2021-02-26 2022-09-07 国立大学法人北海道大学 がんの治療又は予防剤、及びがんの治療又は予防のためのｒｆ経路阻害剤とｍｅｋ阻害剤との組み合わせ
CN114891808B (zh) * 2022-06-21 2023-10-27 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124198A (en) * 1872-03-05 Improvement in devices for cutting off tubes
US19427A (en) * 1858-02-23 Improvement in steam-plows
US1082196A (en) * 1913-04-16 1913-12-23 Alois Helfenstein Electric furnace.
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US5409905A (en) * 1981-01-05 1995-04-25 Eby, Iii; George A. Cure for commond cold
GB2118437B (en) 1982-03-01 1984-12-12 Efamol Ltd Composition for treating alcoholism
US4496548A (en) 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
EP0185117A1 (de) 1984-12-21 1986-06-25 IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH Getränk
GB8521275D0 (en) * 1985-08-27 1985-10-02 Blass D H Therapeutic composition
PH22818A (en) 1986-02-18 1989-01-19 Takeda Chemical Industries Ltd Composition and method for reducing acetaldehyde toxicity
JP2560808B2 (ja) 1988-11-02 1996-12-04 味の素株式会社 アミノ酸及びペッパー抽出物含有酒類
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JP3051413B2 (ja) 1989-07-20 2000-06-12 アルバート・ティー・ナイトー 血液脳関門を通過する物質
CN1058914A (zh) * 1991-03-16 1992-02-26 肖宏生 酒液多功能口服液
JPH04342528A (ja) * 1991-05-17 1992-11-30 Toyama Chem Co Ltd アルコール代謝およびアセトアルデヒド代謝促進剤
US5559152A (en) 1992-07-06 1996-09-24 Komissarova; Irina A. Pharmaceutical composition having antiacoholic activity
RU2012350C1 (ru) * 1993-05-17 1994-05-15 Александр Михайлович Шепеленко Средство для снятия алкогольного опьянения
JPH0733653A (ja) * 1993-06-25 1995-02-03 Suntory Ltd アセトアルデヒド毒性の抑制剤
US5475031A (en) 1993-09-03 1995-12-12 Livingston; William H. Discovery of a valuable property for succinic acid and other intermediary metabolites
GB9526741D0 (en) 1995-12-30 1996-02-28 Sobering Thoughts Ltd Product for combatting dehydration
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
FR2748935A1 (fr) * 1996-05-23 1997-11-28 Clergeaud Jean Solution buvable favorisant la baisse du taux d'alcoolemie
CN1170578A (zh) * 1996-07-17 1998-01-21 中国人民解放军第四军医大学 地龙胶囊
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
US6667063B2 (en) 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
AT411958B8 (de) 1998-11-19 2004-09-27 Jhs Privatstiftung Erfrischungsgetränk zur steigerung der alkohol-abbau-kapazität
WO2001067890A2 (en) 2000-03-14 2001-09-20 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
EP1195159B1 (en) 2000-10-09 2006-05-31 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer
US6630158B2 (en) 2000-10-31 2003-10-07 Stiefel Laboratories, Inc. Dietary supplement composition and method for improving and maintaining healthy skin
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
AUPR626101A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A composition and uses therefor
KR20040013137A (ko) 2001-07-13 2004-02-11 다카라 바이오 가부시키가이샤 치료제
KR20030032484A (ko) * 2001-10-18 2003-04-26 롯데제과주식회사 발암 억제효능을 갖는 데오브로민
JP4119640B2 (ja) * 2001-10-26 2008-07-16 株式会社大塚製薬工場 飲酒時の不快症状軽減剤
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
CN100361599C (zh) * 2002-10-23 2008-01-16 克尔塞根控股有限公司 抗氧化组合物
US6821536B2 (en) * 2002-11-22 2004-11-23 Quercegen Holdings Llc Antioxidative compositions
KR20040045146A (ko) * 2002-11-22 2004-06-01 (주) 내츄로에이스 숙취 제거 및 피로회복을 위한 생약 조성물 및 이를이용한 건강보조식품
KR20040094173A (ko) * 2003-05-02 2004-11-09 장경케어그룹 주식회사 백년초-건조분말 및 이를 포함하는 숙취제거용 조성물
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
US6936283B2 (en) 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
RU2240789C1 (ru) * 2003-12-24 2004-11-27 Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" Средство, обладающее гепатопротекторными свойствами, для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома
PT1720610E (pt) * 2004-02-17 2011-02-10 Matuschka Greiffenclau Markus Graf V Composição moderadora do metabolismo de álcool
US20050238638A1 (en) * 2004-04-21 2005-10-27 Jonathan Gutwein Dietary Supplement that Serves as a Carbohydrate Blocker and Hangover Remedy
US20050238710A1 (en) * 2004-04-23 2005-10-27 Philip Connolly Vitamin replacement as a hangover ameliorative
US20050271754A1 (en) * 2004-06-07 2005-12-08 Cochrane Patrick W Composition for prevention or treatment of an alcohol hangover
US8633192B2 (en) * 2006-12-15 2014-01-21 Tima Foundation Compositions and uses thereof

Also Published As

Publication number Publication date
KR101487848B1 (ko) 2015-02-03
PT1909600E (pt) 2012-07-24
ATE554663T1 (de) 2012-05-15
AU2006278823A1 (en) 2007-02-15
CA2611389A1 (en) 2007-02-15
CA2611389C (en) 2015-02-17
WO2007017139A1 (en) 2007-02-15
KR20130137719A (ko) 2013-12-17
AU2006278823B2 (en) 2011-05-12
HK1117709A1 (en) 2009-01-23
PL1909600T3 (pl) 2012-09-28
US20090054351A1 (en) 2009-02-26
EA012753B1 (ru) 2009-12-30
KR20080033899A (ko) 2008-04-17
JP5371428B2 (ja) 2013-12-18
ES2386460T3 (es) 2012-08-21
CY1113015T1 (el) 2016-04-13
US8580750B2 (en) 2013-11-12
SI1909600T1 (sl) 2012-07-31
UA94713C2 (ru) 2011-06-10
JP2013189437A (ja) 2013-09-26
CN101232822B (zh) 2012-11-14
EP1909600A1 (en) 2008-04-16
EP1909600B1 (en) 2012-04-25
DK1909600T3 (da) 2012-07-30
KR101562271B1 (ko) 2015-10-21
JP5785581B2 (ja) 2015-09-30
HRP20120489T1 (hr) 2012-07-31
US9402849B2 (en) 2016-08-02
CN101232822A (zh) 2008-07-30
JP2009516639A (ja) 2009-04-23
US20140105877A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
EA200800427A1 (ru) Композиция для сдерживания алкогольного обмена веществ и для уменьшения риска алкогольных заболеваний
TW200626576A (en) Bicyclic amides as kinase inhibitors
IL195611A0 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
HK1157337A1 (ru)
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2007125331A3 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TW200628473A (en) Novel heterocycles
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
ATE372776T1 (de) Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit
WO2008135661A3 (fr) Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
WO2007084625A3 (en) Novel compounds and methods for inhibiting p53 activity
WO2008087340A3 (fr) UTILISATION D' OLIGO-β-(1,3)-GLUCANES MODIFIES POUR LE TRAITEMENT DE MALADIES DU SYSTEME IMMUNITAIRE, OLIGO-β-(1,3)-GLUCANE-(1,3)- MANNOSE, OLIGO-β-(1.3)-GLUCANE-(1,3)- MANNITOL ET LEURS DERIVES, LEURS PROCEDES DE PREPARATION ET MEDICAMENTS LES CONTENANT
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM